{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:14Z","timestamp":1790395454404,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Fabry disease is a rare X\u2010linked multisystem disease, with progressive proteinuric kidney disease contributing significantly to morbidity and mortality of these patients. Evidence shows that sodium\u2010glucose cotransporter 2 inhibitors (SGLT2Is) can reduce proteinuria and slow progression to end\u2010stage kidney disease in both diabetic and non\u2010diabetic kidney disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Evaluate the effects of SGLT2I on kidney function and albuminuria in patients with Fabry disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Single\u2010centre real\u2010world case series reviewing electronic medical records of patients with Fabry disease who initiated therapy with dapagliflozin or empagliflozin (<jats:italic>n<\/jats:italic> =\u200911). Changes in urine albumin\u2013creatinine ratio (uACR) and creatinine before and after treatment with SGLT2I were analysed using Wilcoxon signed\u2010rank test. Two\u2010tailed <jats:italic>P<\/jats:italic>\u2010values &lt;0.05 were considered significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven patients were followed for up to 19 months after commencement of SGLT2I. An overall significant reduction in albuminuria (<jats:italic>P<\/jats:italic> =\u20090.05) was seen with SGLT2I use in the Fabry cohort. Median uACR before SGLT2I was 76 mg\/mmol (interquartile range (IQR) 47\u2013141) and after SGLT2I was 39 mg\/mmol (IQR 18\u201395) (<jats:italic>P<\/jats:italic> =\u20090.05). All patients with uACR &gt;100 mg\/mmol had reduction in albuminuria over the study period. SGLT2Is were well tolerated overall, with only one case resulting in cessation of treatment due to adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results suggest SGLT2Is can significantly reduce albuminuria in a portion of patients with Fabry\u2010related kidney disease and offer additional treatment for Fabry nephropathy. Given the nature of the study design and small case numbers, further long\u2010term controlled studies are required to evaluate the long\u2010term efficacy of this medication class in both cardiac and renal outcomes in Fabry disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.16603","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T16:53:42Z","timestamp":1735059222000},"page":"617-621","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sodium\u2010glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real\u2010world case series"],"prefix":"10.1111","volume":"55","author":[{"given":"Anthea","family":"Tsatsaronis","sequence":"first","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tiong","sequence":"additional","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6580-1464","authenticated-orcid":false,"given":"Irene","family":"Ruderman","sequence":"additional","affiliation":[{"name":"Department of Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11020271"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019050497"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13650"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.013"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213473"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2020.1841281"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051675"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05694-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_2_8_16_1","volume-title":"GeneReviews(\u00ae)","author":"Mehta A","year":"1993"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70442-7"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113689"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T10:17:19Z","timestamp":1746872239000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/imj.16603"],"URL":"https:\/\/doi.org\/10.1111\/imj.16603","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"2024-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}